Our group previously performed targeted in vivo CRISPR/Cas9 genetic screening, which led to the identification of the protein arginine methyltransferase 5 (PRMT5) as a possible therapeutic target against pancreatic cancer when combined with Gem [7,8]. This evidence concerns the gene PRMT5 and pancreatic neoplasm.